We further found that the effects of RUNX2 are mediated through the activation of MGAT5 and MMP13 both in vitro and in vivo, as their overexpression could compensate for RUNX2 depletion in gastric cancer cell lines and xenograft tumor models. This evidence concerns the gene MMP13 and neoplasm.